SEQUENTIAL MOLECULAR MONITORING OF CHIMERISM IN CHRONIC MYELOID-LEUKEMIA PATIENTS RECEIVING DONOR LYMPHOCYTE TRANSFUSION FOR RELAPSE AFTER BONE-MARROW TRANSPLANTATION
Mc. Rapanotti et al., SEQUENTIAL MOLECULAR MONITORING OF CHIMERISM IN CHRONIC MYELOID-LEUKEMIA PATIENTS RECEIVING DONOR LYMPHOCYTE TRANSFUSION FOR RELAPSE AFTER BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 19(7), 1997, pp. 703-707
Recent observations of chimerism in patients relapsed following an all
otransplant suggest the persistence of immunotolerance, thus offering
a biologic rationale for the use of donor lymphocyte transfusion (DLT)
, In this study, we have analyzed by PCR amplification of several VNTR
regions, sequential bone marrow and peripheral blood DNA samples in f
our patients who received DLT for CR IL relapse after bone marrow tran
splantation. Prior to DLT, all patients showed mixed chimerism in peri
pheral blood cells while two had mixed chimerism and two no chimerism
in the PM, None of these four patients showed evidence of chimerism at
the cytogenetic level (all had 100% +ve metaphases), After DLT, a com
plete hematologic and molecular remission (ie disappearance of the BCR
/ABL fusion transcript) was obtained in the two patients who had bone
marrow mixed chimerism prior to DLT, The two patients without evidence
of marrow chimerism prior to DLT converted to a pattern of mixed chim
erism after DLT, but both developed a severe bone marrow aplasia occur
ring at day 56 and 36, respectively, With regard to the sequential ana
lysis of bone marrow chimerism after DLT we observed that: (1) the dis
appearance of BCR/ABL +ve cells paralleled the conversion to a pattern
of full donor chimerism; and (2) the time interval to achieve CR was
inversely correlated with the percentage of donor DNA in bone marrow,
In conclusion, we have shown here that the assessment of bone marrow p
re-DLT chimerism by PCR analysis might predict the response in patient
s with favorable characteristics, and also might identify patients at
high risk of developing severe myelosuppression.